In a nutshell This study examined how well brentuximab vedotin (Adcetris) plus high-dose bendamustine (Treanda) worked in patients with recurrent or non-responsive classical Hodgkin’s lymphoma (cHL). This study concluded that this regimen was highly effective for these patients. Some background After initial treatment, many patients with cHL...
Read More
In a nutshell This phase 2 study evaluated the effectiveness and safety of camrelizumab alone or in combination with decitabine (Dacogen) for recurrent or non-responsive classical Hodgkin’s lymphoma (cHL). This study concluded that the combined treatment was safe and highly effective in these patients. Some background Standard first-line...
Read More
In a nutshell This phase 2 trial is examining the effectiveness and safety of DS-8201a in the treatment of advanced HER2 positive colorectal cancer. The main outcome to be measured is the tumor response to the treatment and side effects. The details The standard treatment to advanced colorectal cancers is surgery, chemotherapy and radiation...
Read MoreIn a nutshell This trial is examining the safety and effectiveness of combination therapy with pembrolizumab (Keytruda) and lenvatinib (Lenvima) for advanced or unresponsive colorectal cancer (CRC) and other solid tumors. The main outcome to be measured will be the objective response rate (ORR; the percentage of participants who have complete...
Read More
In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) plus lenalidomide (Revlimid) for patients with recurrent or non-responsive non-Hodgkin’s lymphoma (NHL). This study concluded that lenalidomide was well-tolerated and improved the effectiveness of rituximab in these patients. Some background Follicular...
Read More
In a nutshell This study evaluated the effectiveness of BEAM chemotherapy versus BUCYVP16 chemotherapy in patients with non-Hodgkin’s lymphoma (NHL) before autologous stem cell transplantation (ASCT). This study concluded that these regimens were similarly safe and effective for these patients before ASCT. Some background For patients with NHL...
Read MoreIn a nutshell This trial will evaluate the effects of a new treatment parsaclisib (INCB050465) in relapsed or unresponsive follicular lymphoma (FL). Response rate, survival, and side effects will be the main outcomes measured. The details Many patients are cured with treatments for follicular lymphoma (FL). Some, however, lose response to therapy...
Read More
In a nutshell This trial is examining the effectiveness of circulating cell-free tumor DNA (cCFTD) as a predictive factor for the treatment of advanced colorectal cancer with regorafenib (Stivarga) or TAS-102. The main outcome to be measured will be to evaluate the ability of early change of cCFTD after the start of the treatment. This trial will be...
Read More
In a nutshell This study evaluated the long-term outcomes of patients with recurrent or non-responsive classical Hodgkin’s lymphoma (cHL) after undergoing radiation, chemotherapy, and autologous stem cell transplantation (autoSCT). This study concluded that total lymphoid irradiation (TLI) therapy before a bone marrow transplant can improve...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of a combination of clarithromycin, pomalidomide, and dexamethasone (the ClaPd regime) in patients with relapsed/unresponsive multiple myeloma who had been treated with lenalidomide. This study concluded that this combination is as effective as other currently used...
Read More
In a nutshell This study investigated the effectiveness of pertuzumab (Perjeta) and trastuzumab (Herceptin) in patients with colorectal cancer and HER2 mutation (an abnormal gene). Researchers suggested that this treatment could be a safe option for patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC). Some background...
Read More
In a nutshell This study is evaluating the best dose and side effects of mogamulizumab (Poteligeo) plus pembrolizumab (Keytruda) for relapsed or unresponsive lymphoma. The main outcomes to be measured will be the best dose and side effects of treatment, as well as survival without the tumor growing. This study is being conducted in Sacramento,...
Read More
